Jalyn approved for benign prostatic hyperplasia (BPH)

Share this content:
Jalyn approved for benign prostatic hyperplasia (BPH)
Jalyn approved for benign prostatic hyperplasia (BPH)

The FDA has approved GlaxoSmithKline's Jalyn, a fixed dose combination of dutasteride and tamsulosin, for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. This approval was based on two-year results from the international, multicenter, randomized, double-blind and parallel-group CombAT (Combination of Avodart and Tamsulosin) study conducted in 4,844 men with BPH.  The study compared changes in urinary symptoms seen with dutasteride co-administered with tamsulosin as opposed to either medicine alone. 

Jalyn is expected to be made available in a dutasteride 0.5mg/tamsulosin 0.4mg dosage strength capsule during the second half of 2010.

For more information call (888) 825-5239 or visit www.gsk.com.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs